Multiple other studies have investigated the efficacy of RGD and NGR-targeted coaguligands, primarily fused to the C-terminal region of tTF, with pre-clinical testing performed in human breast cancer (SKBR3 and MDA-MB-435), lung adenocarcinoma (A549 and MAD109), human fibrosarcoma (HT1080), glioblastoma (U87), melanoma (M21), small cell lung cancer (HTB119), and colorectal (CT26) cancer models (Table S1) [14,76,77,78,79,80,81,82,83]. This evidence concerns the gene RHOH and melanoma.